APUDomas: acute complications and their medical management.
APUDomas are rare tumours originating from a variety of endocrine cells localized in different organs. Acute complications from APUDomas usually result from the increased biosynthesis and release of bioactive amines or polypeptide hormones by the tumour. Less frequently, bleeding or compression by the tumour can occur requiring emergency surgery. Increased gastrin production by gastrinomas is the cause of ZES (peptic ulceration and diarrhoea) by gastrin effects on gastric acid secretion. Volume depletion, hypokalaemia, severe bleeding, duodenal perforation, oesophageal stricture and pyloric stenosis are the most dramatic complications. Treatment of these complications and their prevention has been facilitated by the availability of antagonists to H2 receptors and H(+)-K+ proton pump. These medications should control acid output in every patient with ZES. Frequent manifestations of carcinoid tumours, VIPomas and medullary thyroid carcinomas are flushing and diarrhoea. Octreotide, a long-acting somatostatin analogue, has markedly changed the management of these patients, their symptoms decreasing in severity or disappearing in most cases. Octreotide has also been used with success in the prevention and treatment of the carcinoid crisis, a dreaded complication of carcinoid tumours. A better understanding of the pathophysiology of APUDomas has enabled new treatment designs which have considerably ameliorated the quality of life of patients affected by these tumours; efforts must be continued to affect their life expectancy.
Philippe
J
J
D000208:Acute Disease; D001079:Apudoma / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D002276:Carcinoid Tumor / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D004701:Endocrine Gland Neoplasms / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D013964:Thyroid Neoplasms / Q000628:therapy; D003969:Vipoma / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D015043:Zollinger-Ellison Syndrome / Q000150:complications / Q000175:diagnosis / Q000628:therapy